Compare ADPT & BCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | BCC |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | 7680 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | RETAIL: Building Materials |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2019 | 2012 |
| Metric | ADPT | BCC |
|---|---|---|
| Price | $21.28 | $75.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $17.78 | ★ $99.20 |
| AVG Volume (30 Days) | ★ 4.0M | 396.7K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ 0.50 |
| Revenue | $276,976,000.00 | ★ $4,995,290,000.00 |
| Revenue This Year | $3.98 | $3.41 |
| Revenue Next Year | $22.72 | $4.76 |
| P/E Ratio | ★ N/A | $151.86 |
| Revenue Growth | ★ 54.77 | 12.71 |
| 52 Week Low | $9.96 | $65.00 |
| 52 Week High | $22.80 | $95.00 |
| Indicator | ADPT | BCC |
|---|---|---|
| Relative Strength Index (RSI) | 66.83 | 55.21 |
| Support Level | $15.08 | $71.49 |
| Resistance Level | N/A | $78.96 |
| Average True Range (ATR) | 1.27 | 2.88 |
| MACD | 0.33 | 0.47 |
| Stochastic Oscillator | 76.67 | 49.84 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.